Life-threatening anaphylaxis following antivenom administration in two patients with horse dander allergy.

Overview

• This research article reports two cases where patients with known horse dander allergies experienced life-threatening anaphylaxis after receiving antivenom derived from horses.
• The study highlights the potential cross-reactivity between horse dander allergens and horse-derived antivenom, emphasizing the importance of allergy screening before treatment.

Background

• Antivenom is a treatment for systemic envenomation caused by venomous bites or stings.
• It typically consists of immunoglobulin G (IgG) antibodies that are produced by animals, usually horses, exposed to venom to stimulate antibody generation.
• Although antivenom is effective in neutralizing venom, it can cause allergic reactions due to its animal origin.

Case Reports

• Case 1: A 14-year-old boy with a known horse dander allergy was bitten by a redback spider and given antivenom to relieve severe pain.
• He developed immediate severe anaphylaxis, which required intensive medical interventions including endotracheal intubation and inotropic support to stabilize his condition.
• Case 2: A 52-year-old man with a history of horse dander allergy received antivenom after a suspected snakebite.
• He immediately developed profound anaphylaxis, suffered a prolonged cardiac arrest, and subsequently died due to multiorgan failure caused by hypoxia (lack of oxygen).

Interpretation of Findings

• Severe anaphylactic reactions following antivenom administration are rare in Australia.
• However, individuals with allergies to horse dander appear to be at higher risk of severe anaphylaxis when treated with horse-derived antivenom.
• The increased risk is likely due to cross-reactivity—where allergens in both horse dander and horse serum (used to make antivenom) share similar proteins that trigger allergic immune responses.

Clinical Implications

• Recognition of horse dander allergy as a potential risk factor for antivenom-induced anaphylaxis is critical to improve patient safety.
• Healthcare providers should specifically ask patients about allergies to horse dander before antivenom administration.
• Such allergy screening allows better risk-benefit analysis concerning antivenom treatment decisions, potentially preventing life-threatening allergic reactions.
• Alternative treatments or premedication strategies might be considered for at-risk patients to mitigate the chance of anaphylaxis.

Summary

• This article highlights that horse dander allergy may predispose patients to severe, even fatal, anaphylaxis when treated with horse-derived antivenom.
• It underscores the importance of allergy history taking as part of clinical protocols when administering antivenom.
• Further research is needed to explore safer antivenom formulations or preventive approaches in allergic patients.